Hercules Capital, Inc. 6.25% Notes due 2033
HCXYDividend History
Investors can expect a dividend payout of $0.39 per share, scheduled to be distributed in 41 days on January 30, 2026
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| January 30, 2026 | $0.39 | 2026-01-15 | 2026-01-15 |
| October 30, 2025 | $0.39 | 2025-10-15 | 2025-10-15 |
| July 30, 2025 | $0.39 | 2025-07-15 | 2025-07-15 |
| April 30, 2025 | $0.39 | 2025-04-15 | 2025-04-15 |
| January 30, 2025 | $0.39 | 2025-01-15 | 2025-01-15 |
Dividends Summary
- Hercules Capital, Inc. 6.25% Notes due 2033 has issued 26 dividend payments over the past 7 years
- The most recent dividend was paid 51 days ago, on October 30, 2025
- The highest dividend payed out to investors during this period was $0.39 per share
- The average dividend paid during this period was $0.39 per share.
Company News
MoonLake Immunotherapeutics reported Q3 2025 financial results, highlighting positive clinical trial data for its Nanobody® sonelokimab in treating inflammatory diseases like hidradenitis suppurativa, psoriatic arthritis, and palmoplantar pustulosis. The company ended the quarter with $380.5 million in cash and expects funding into the second ha...
Sound Income Strategies sold 177,473 shares of Hercules Capital for approximately $3.40 million in Q3 2025, reducing its stake while maintaining over 2.7 million shares. Hercules Capital has underperformed the S&P 500 over the past year.
Hercules Capital Inc.'s Q2 2024 net investment income matched estimates, but declined year-over-year due to higher operating expenses. The company's total investment income and portfolio value remained strong, but expenses rose due to increased interest and compensation costs.
Eloxx Pharmaceuticals, a biopharmaceutical company, has secured an additional $3.175 million in funding through a loan agreement amendment with Hercules Capital and other lenders. The funding will be used for the company's operations and development of its ELX-02 compound.
